184 related articles for article (PubMed ID: 28272215)
1. No association between metformin use and survival in patients with pancreatic cancer: An observational cohort study.
Frouws MA; Sibinga Mulder BG; Bastiaannet E; Zanders MMJ; van Herk-Sukel MPP; de Leede EM; Bonsing BA; Mieog JSD; Van de Velde CJH; Liefers GJ
Medicine (Baltimore); 2017 Mar; 96(10):e6229. PubMed ID: 28272215
[TBL] [Abstract][Full Text] [Related]
2. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetes Care; 2012 Jan; 35(1):119-24. PubMed ID: 22100960
[TBL] [Abstract][Full Text] [Related]
3. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
Johnson JA; Majumdar SR; Simpson SH; Toth EL
Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
5. Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea.
Baker MC; Sheth K; Liu Y; Lu D; Lu R; Robinson WH
JAMA Netw Open; 2023 Mar; 6(3):e233646. PubMed ID: 36939700
[TBL] [Abstract][Full Text] [Related]
6. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
7. Predictors of insulin initiation in metformin and sulfonylurea users in primary care practices: the role of kidney function.
Kostev K; Dippel FW; Rathmann W
J Diabetes Sci Technol; 2014 Sep; 8(5):1023-8. PubMed ID: 24876433
[TBL] [Abstract][Full Text] [Related]
8. Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival.
Dulskas A; Patasius A; Linkeviciute-Ulinskiene D; Zabuliene L; Smailyte G
Int J Environ Res Public Health; 2020 Aug; 17(17):. PubMed ID: 32824907
[TBL] [Abstract][Full Text] [Related]
9. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
Kowall B; Rathmann W; Kostev K
Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
[TBL] [Abstract][Full Text] [Related]
10. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
Tseng CH
Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
Raju A; Shetty S; Cai B; D'Souza AO
J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
[TBL] [Abstract][Full Text] [Related]
12. Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study.
Cho J; Scragg R; Pandol SJ; Goodarzi MO; Petrov MS
Diabetes Care; 2019 Sep; 42(9):1675-1683. PubMed ID: 31227582
[TBL] [Abstract][Full Text] [Related]
13. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study.
Andersson C; Olesen JB; Hansen PR; Weeke P; Norgaard ML; Jørgensen CH; Lange T; Abildstrøm SZ; Schramm TK; Vaag A; Køber L; Torp-Pedersen C; Gislason GH
Diabetologia; 2010 Dec; 53(12):2546-53. PubMed ID: 20838985
[TBL] [Abstract][Full Text] [Related]
14. Metformin and survival in pancreatic cancer: a retrospective cohort study.
Hwang AL; Haynes K; Hwang WT; Yang YX
Pancreas; 2013 Oct; 42(7):1054-9. PubMed ID: 24051965
[TBL] [Abstract][Full Text] [Related]
15. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.
Eurich DT; Simpson SH; Majumdar SR; Johnson JA
Pharmacotherapy; 2005 Jun; 25(6):810-6. PubMed ID: 15927899
[TBL] [Abstract][Full Text] [Related]
16. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
17. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
18. Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer.
Murff HJ; Roumie CL; Greevy RA; Hackstadt AJ; McGowan LED; Hung AM; Grijalva CG; Griffin MR
Cancer Causes Control; 2018 Sep; 29(9):823-832. PubMed ID: 30022336
[TBL] [Abstract][Full Text] [Related]
19. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
[TBL] [Abstract][Full Text] [Related]
20. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2.
Lee SH; Yoon SH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; Bang S
Dig Liver Dis; 2016 Apr; 48(4):435-40. PubMed ID: 26775128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
